PROX1 and leukemia: To further substantiate the clinical significance of the m6A-assicated lncRNAs in leukemia, we also examined the expression of LN989, PROX1-AS1, SENCR, LN892 and KIF25-AS1 in AML patients, who received nilotinib twice daily after induction and consolidation chemotherapy.(36) We observed that nilotinib (in combination with chemotherapy) upregulates LN989, PROX1-AS1, SENCR, LN892 and KIF25-AS1 (Figure 3D).